Shaving of Cartilage (Chondroplasty) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Shaving of cartilage, formally termed arthroscopic chondroplasty or articular cartilage debridement, is a minimally invasive surgical procedure in which a surgeon uses a motorised shaver, radiofrequency probe, or manual curette — introduced through small arthroscopic portals — to smooth, trim, and stabilise damaged or fraying articular (hyaline) cartilage within a synovial joint. The goal is to remove unstable cartilage flaps and fibrillated tissue that cause mechanical irritation, inflammatory synovitis, and pain, thereby restoring a more stable cartilage surface and reducing intra-articular inflammation.

Articular cartilage is the smooth, glistening white tissue that covers the ends of bones in movable joints. Unlike bone, it has virtually no intrinsic blood supply or nerve supply, which accounts for both its pain insensitivity at the chondral level and its very limited capacity for spontaneous regeneration. Damage to articular cartilage is graded using the International Cartilage Repair Society (ICRS) classification or the Outerbridge grading system: Grade I (softening and surface irregularity); Grade II (partial-thickness fissures not reaching subchondral bone); Grade III (deep fissures reaching subchondral bone without exposed bone); Grade IV (full-thickness loss with exposed subchondral bone). Chondroplasty is most appropriate for Grade I to III lesions; Grade IV lesions with significant bone exposure typically require cartilage regeneration or replacement procedures.

The knee is the most commonly treated joint — chondroplasty is frequently performed on the medial or lateral femoral condyle, the patella, and the trochlear groove — but the technique is also applied in the hip, shoulder, ankle, and elbow. Chondroplasty is frequently performed concurrently with other arthroscopic procedures such as meniscal repair or partial meniscectomy, ACL reconstruction, or synovectomy when multiple intra-articular pathologies co-exist. As a palliative or temporising procedure, it reliably achieves short-to-medium-term symptom improvement in appropriately selected patients, but does not regenerate hyaline cartilage or halt the natural progression of early osteoarthritis in most cases.

Arthroscopic chondroplasty is indicated for a specific subset of articular cartilage pathologies where mechanical symptoms dominate and the lesion characteristics — particularly depth, size, and location — suggest that debridement and stabilisation of the unstable cartilage margin will yield meaningful clinical benefit. The primary conditions include:

• Focal Chondral Lesions (Grade I to III): Discrete areas of cartilage softening, fibrillation, or partial-thickness fissuring resulting from acute trauma (such as a twisting sports injury or dashboard impact), repetitive overload, or early degenerative change. The unstable frayed edges mechanically irritate the synovium and opposing cartilage surfaces with every joint movement, generating an inflammatory cascade that produces pain and effusion.
• Chondromalacia Patellae: Softening and fibrillation of the articular cartilage on the posterior surface of the patella, typically affecting young active adults and causing anterior knee pain, crepitus, and pain with stairs and squatting. Grades II and III with a clearly identifiable unstable flap and failure of conservative management are the most appropriate candidates for chondroplasty.
• Degenerative Arthritis — Early to Moderate Stage: Osteoarthritis involving generalised articular cartilage fibrillation without full-thickness loss, particularly in patients with mechanical symptoms (locking, catching, giving way) that suggest an unstable cartilage fragment contributing disproportionately to symptoms beyond the baseline arthritic process. The evidence for routine chondroplasty in undifferentiated osteoarthritis pain is weak; appropriate patient selection focused on the mechanical symptom component is critical.
• Post-Traumatic Chondral Injury: Following acute joint trauma — ligament ruptures, patellar dislocations, tibial plateau fractures — articular cartilage injuries are common concurrent findings. Chondroplasty of co-existing chondral lesions during arthroscopic ligament or meniscal surgery is standard practice, addressing all intra-articular pathology during a single anaesthetic episode.
• Osteochondral Lesion Borders: At the margins of osteochondral defects being treated by microfracture or osteochondral grafting, chondroplasty of the unstable surrounding cartilage edge is routinely performed as part of lesion preparation to create stable vertical walls that improve fibrocartilage fill retention and optimise the interface between new repair tissue and surrounding native cartilage.
• Hip and Shoulder Impingement Syndromes: Femoroacetabular impingement (FAI) and shoulder impingement frequently generate chondral damage at characteristic anatomical locations. Hip arthroscopic surgery for FAI routinely includes chondroplasty of cam-related acetabular chondral injury alongside labral repair and osseous reshaping.

Careful patient selection is the most important determinant of outcome after chondroplasty. The procedure produces the best results when mechanical symptoms — rather than diffuse inflammatory or advanced degenerative pain — are the dominant clinical complaint, and when the lesion characteristics are consistent with an unstable chondral flap or fibrillated zone amenable to debridement. Key eligibility criteria and assessment principles are outlined below:

• Persistent Mechanical Symptoms After Conservative Treatment: Candidates should typically have undergone a structured trial of conservative management — physiotherapy (quadriceps and hip abductor strengthening, proprioception training), activity modification, NSAIDs, and intra-articular corticosteroid or hyaluronic acid injection — for a minimum of 3 to 6 months without adequate symptom resolution. Isolated mechanical symptoms such as catching, locking, and giving way may warrant earlier surgical consideration where a discrete unstable flap is clearly identified on MRI.
• Imaging-Confirmed Focal or Partial-Thickness Lesion: MRI with cartilage-sensitive sequences (T2 mapping, dGEMRIC, or 3D DESS) and/or diagnostic arthroscopy findings should confirm a focal chondral lesion of appropriate grade (ICRS I to III preferred) at a mechanically plausible location for the patient's symptom pattern. Lesion size, depth, location, and the condition of the surrounding cartilage all influence prognosis.
• Absence of Advanced Diffuse Osteoarthritis: Chondroplasty provides limited and unpredictable benefit in joints with Kellgren-Lawrence grade III or IV osteoarthritis on plain radiographs, loss of joint space, or extensive subchondral bone changes. In advanced OA, joint replacement is the more appropriate intervention for pain relief and functional restoration.
• Appropriate Alignment: Significant malalignment — varus or valgus deformity exceeding 5 to 7 degrees — concentrates load on the affected compartment and substantially reduces the durability of chondroplasty results. Concurrent or staged osteotomy (high tibial osteotomy or distal femoral osteotomy) is required to off-load the affected compartment and optimise outcomes in patients with significant mechanical axis deviation.
• Medical Fitness for Arthroscopic Surgery: Standard anaesthetic and surgical fitness assessment is required. The procedure is safe for a broad age range (typically 15 to 65 years for chondroplasty as primary treatment; older patients considered case-by-case). Obesity (BMI greater than 35) increases technical difficulty and complication risk. Active joint infection is an absolute contraindication.
• Realistic Patient Expectations: Chondroplasty is a palliative and temporising procedure. It reliably improves mechanical symptoms in appropriately selected patients but does not restore native hyaline cartilage, does not halt osteoarthritis progression, and cannot be expected to return all patients to pre-injury sport levels, particularly where the underlying cartilage lesion is large or the joint is arthritic.

Arthroscopic chondroplasty is performed under general or spinal anaesthesia as a day-case procedure. The operative technique involves the following principal steps and tool choices:

• Arthroscopic Access and Diagnostic Survey: Two to four small skin incisions (portals, typically 5 to 10 mm) provide access for the arthroscope camera and working instruments. A thorough diagnostic arthroscopy is performed first, systematically inspecting all articular surfaces, menisci, ligaments, and synovium to identify all relevant pathology. Chondral lesion grade, size, location, and the condition of surrounding cartilage are confirmed under direct visualisation and tactile probing.
• Unstable Tissue Removal with Motorised Shaver: A powered arthroscopic shaver with a rounded, fenestrated tip rotates at controlled speed to selectively debride and aspirate fibrillated, frayed, or flap cartilage tissue. The surgeon advances the shaver carefully to create smooth, stable cartilage margins, removing all mechanically unstable tissue while preserving as much healthy surrounding cartilage as possible.
• Radiofrequency Chondroplasty: Radiofrequency (RF) probes using monopolar or bipolar energy can smooth the cartilage surface through controlled thermal ablation of fibrillated tissue fibres. RF chondroplasty produces a smooth, sealed surface but generates thermal energy that — if applied incorrectly — may damage adjacent healthy chondrocytes. Multiple studies comparing mechanical shaving to RF chondroplasty have not demonstrated a consistent clinical superiority of either technique; the choice is based on lesion characteristics and surgeon preference.
• Lesion Margin Preparation: After removing the central unstable tissue, the surgeon creates perpendicular, stable vertical margins (walls) around the lesion perimeter using a curette or ring curette. These walls are critical if the chondroplasty is being combined with a marrow stimulation technique (microfracture), as stable containment promotes clot retention and fibrocartilage fill.
• Concurrent Procedures: Chondroplasty is commonly performed alongside partial meniscectomy or meniscal repair, synovectomy, loose body removal, ACL reconstruction, patellofemoral stabilisation, or labral repair in the hip — addressing all identified intra-articular pathology during a single surgical session.
• Wound Closure and Post-Operative Injection: Portal sites are closed with sutures or steri-strips. An intra-articular injection of local anaesthetic with or without corticosteroid is commonly instilled at the end of the procedure to provide immediate post-operative pain control. A soft compressive bandage and ice pack are applied.

When applied to appropriately selected patients with focal cartilage pathology and dominant mechanical symptoms, arthroscopic chondroplasty offers a well-characterised profile of clinical benefits:

• Rapid and Reliable Mechanical Symptom Relief: Removal of unstable cartilage flaps eliminates the mechanical impingement and synovial irritation responsible for catching, locking, and giving-way episodes. Mechanical symptom improvement is typically experienced within the first 4 to 6 weeks post-operatively and is the most consistent positive outcome of the procedure in appropriately selected patients.
• Reduced Intra-Articular Inflammation: Fibrillated, degenerate cartilage fragments shed particulate debris into the synovial fluid, perpetuating chronic synovitis and accelerating articular cartilage wear. Chondroplasty reduces this debris load, decreasing synovial inflammation, joint effusion, and associated pain in the short to medium term.
• Minimally Invasive, Day-Case Procedure: Performed through portals of less than 1 cm, chondroplasty avoids the morbidity of open joint surgery. Day-case discharge, rapid return to mobilisation, and a short rehabilitation course make the procedure logistically accessible and associated with high patient satisfaction in terms of the surgical experience.
• Concurrent Treatment of Multiple Pathologies: A single arthroscopic session allows simultaneous treatment of co-existing pathology — meniscal tears, loose bodies, synovitis, impingement lesions — that would otherwise require multiple procedures, substantially improving the overall outcome in patients with complex intra-articular disease.
• Bridge to Definitive Reconstruction: In young patients with focal Grade III or IV chondral defects who are not yet appropriate for joint replacement, chondroplasty combined with marrow stimulation (microfracture) serves as an effective bridge, reducing symptoms and preserving joint function while the patient matures or accumulates evidence for more complex cartilage restoration procedures such as MACI or osteochondral grafting.
• Low Complication Rate: The procedure carries a low rate of serious complications. Post-operative infection, thromboembolic events, and nerve injury are rare. The minimally invasive nature substantially limits wound-related complications compared to open surgical alternatives.

While generally safe, arthroscopic chondroplasty carries procedure-specific limitations and a defined set of potential risks that patients should understand before consenting to surgery:

• Limited Durability in Osteoarthritis: Perhaps the most important limitation: chondroplasty does not halt the underlying degenerative process in osteoarthritic joints. Symptom improvement in patients with diffuse OA is often partial and may last only 12 to 24 months before symptoms return as the arthritic process continues. Evidence from the landmark METEOR and FIDELITY trials demonstrates that arthroscopic debridement provides no clinically meaningful benefit over conservative treatment for undifferentiated osteoarthritic knee pain, underscoring the critical importance of appropriate patient selection.
• Chondrocyte Damage from Radiofrequency Energy: Radiofrequency probes generate heat that, if applied excessively or at temperatures above 55°C, can cause chondrocyte death in the adjacent cartilage zone being treated. Careful temperature control and probe movement technique are required to avoid iatrogenic cartilage injury.
• Post-Operative Effusion and Synovitis: Joint swelling and effusion are expected and normal in the first 2 to 6 weeks after arthroscopy. Persistent effusion beyond 6 weeks warrants clinical review and may indicate a reactive synovitis or inadequate post-operative rehabilitation.
• Infection (Septic Arthritis): Post-arthroscopic septic arthritis is rare (0.1 to 0.42% in most series) but represents a serious complication requiring emergency joint washout and prolonged antibiotic therapy. Standard sterile surgical technique and prophylactic antibiotics reduce this risk.
• Thromboembolic Events: Deep vein thrombosis (DVT) and pulmonary embolism (PE) can occur after any lower limb surgery. Risk is proportional to the extent of the procedure, tourniquet time, patient mobility, and individual risk factors. Pharmacological and mechanical thromboprophylaxis is used according to institutional protocol.
• Failure to Resolve Pain: In patients with diffuse articular disease, significant malalignment, established osteoarthritis, or a cartilage lesion that is primarily full-thickness (Grade IV), chondroplasty alone frequently fails to provide meaningful pain relief. Careful pre-operative assessment minimises but cannot eliminate this risk.
• Progression to Joint Replacement: A proportion of patients undergoing chondroplasty for early OA will progress over time to require total or unicompartmental knee replacement. Chondroplasty neither accelerates nor prevents this progression in most cases — it serves as temporising symptom management during the interim period.

Recovery from arthroscopic chondroplasty follows a structured rehabilitation pathway that is tailored to the specific joint, the extent of the chondroplasty, and any concurrent procedures performed. The general milestones are as follows:

• Immediate Post-Operative Phase (Days 0 to 2): Most patients are discharged home on the day of surgery. Crutches are used for 24 to 48 hours to allow initial comfort with weight-bearing. Ice packs applied for 20 minutes every 2 to 3 hours and limb elevation reduce swelling and pain. Oral analgesics (paracetamol, NSAIDs) manage post-operative pain. Wound checks are performed in the first 24 to 48 hours.
• Early Mobilisation Phase (Days 3 to 14): Patients progress to full weight-bearing as tolerated, usually within 1 to 2 weeks for standalone chondroplasty. Active range-of-motion exercises, quadriceps activation, and straight-leg raises commence within the first week to prevent muscle atrophy and maintain joint mobility. Portal suture or steri-strip removal occurs at 10 to 14 days.
• Rehabilitation Phase (Weeks 2 to 6): Formal physiotherapy begins — focused on restoring full range of motion, progressive lower limb strengthening (quadriceps, hamstrings, hip abductors), proprioception and neuromuscular training, and graduated cardiovascular exercise. Hydrotherapy (pool physiotherapy) is particularly beneficial in this phase, allowing strengthening and range of motion work in a reduced weight-bearing environment.
• Return to Activity Phase (Weeks 6 to 12): Return to low-impact activities such as cycling and swimming typically occurs by weeks 4 to 6. Return to running, recreational sport, and higher-impact activities is guided by clinical assessment of pain, effusion, and functional strength testing — usually achievable by 6 to 12 weeks for standalone chondroplasty. Concurrent procedures (ACL reconstruction, extensive meniscal work) extend this timeline substantially.
• Outcome Review: A clinical follow-up appointment at 6 to 12 weeks assesses symptom improvement, functional progress, and guides progression of rehabilitation. Validated outcome scores including the Knee injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC) score, and VAS pain score are used to objectively document clinical change.
• Long-Term Monitoring: Annual clinical review monitors for recurrent symptoms, effusion suggesting progressive chondral deterioration, and radiographic progression of osteoarthritis. Early identification of deterioration allows timely planning for staged cartilage restoration procedures or eventual joint replacement in younger patients.

The cost of arthroscopic chondroplasty varies considerably depending on geographical location, hospital type, extent of the procedure, and concurrent pathologies treated. Prospective patients should consider all of the following factors when budgeting for treatment:

• Country and Healthcare Setting: In the United States, arthroscopic knee chondroplasty typically costs USD 3,000 to USD 8,000 for standalone procedures, rising to USD 10,000 to USD 20,000 with surgeon fees, anaesthesiologist fees, and facility charges included. In the United Kingdom, private arthroscopic knee surgery costs GBP 4,000 to GBP 9,000. India represents one of the highest-value destinations for international patients, with total costs typically ranging from INR 60,000 to INR 1,80,000 (approximately USD 700 to USD 2,200), including hospitalisation, at JCI-accredited centres.
• Concurrent Procedures: When chondroplasty is combined with partial meniscectomy, synovectomy, loose body removal, or other arthroscopic work, the overall surgical fee increases proportionally with the complexity and duration of the procedure. Patients should obtain an itemised quote covering all anticipated components of the surgical episode.
• Anaesthesia Type: General anaesthesia is more expensive than spinal or regional anaesthesia. Some centres perform simple chondroplasty under local anaesthesia with sedation, which is the most cost-effective option where clinically appropriate.
• Pre-Operative Investigations: MRI scan (typically USD 500 to USD 2,500 in the USA; INR 5,000 to INR 20,000 in India), X-rays, blood tests, and an anaesthetic pre-assessment consultation represent significant pre-operative costs to factor into total treatment expenditure.
• Implants and Specialised Equipment: If chondroplasty is combined with microfracture (no implant required) or osteochondral grafting (OATs, allograft — substantial implant cost), or if a radiofrequency system is used, equipment costs add to the overall bill. MACI (matrix-induced autologous chondrocyte implantation) is substantially more expensive given the laboratory cell culture component.
• Physiotherapy and Rehabilitation: Post-operative physiotherapy — typically 8 to 16 sessions over 6 to 12 weeks — represents an important ongoing cost. Budget for this alongside the surgical episode rather than as an afterthought.
• Health Insurance Coverage: Many private health insurers and public health schemes (NHS, Medicare, Medicaid) cover medically indicated chondroplasty with appropriate diagnosis coding. Cosmetic or elective procedures without adequate clinical indication documentation may be declined. Obtain pre-authorisation and confirm coverage scope before scheduling surgery.

Cartilage shaving is one procedure within a spectrum of interventions for articular cartilage damage. Depending on lesion grade, size, patient age, activity demands, and overall joint status, several alternative or supplementary approaches may be more appropriate:

• Conservative Management (First-Line): Structured physiotherapy with quadriceps and hip strengthening, activity modification, weight management, NSAIDs, and bracing can effectively manage Grade I to II chondral lesions and early OA. Conservative management is always the appropriate first step before surgical consideration, with a minimum 3 to 6-month trial in most patients.
• Intra-Articular Injections: Corticosteroid injections provide short-term (4 to 12 weeks) pain and effusion relief. Hyaluronic acid (viscosupplementation) injections may provide longer-lasting symptom reduction in early to moderate OA through lubrication and possible chondroprotective effects. Platelet-rich plasma (PRP) injections have demonstrated promise in randomised trials for symptomatic chondral disease and early OA, with a growing evidence base supporting their use.
• Microfracture: For Grade III to IV full-thickness chondral defects, microfracture stimulates fibrocartilage fill by creating multiple perforations through the subchondral bone to access marrow elements. It is frequently combined with chondroplasty of the lesion margin and is most reliable in lesions under 2 to 4 cm2 in patients under 40 years of age. Fibrocartilage produced is mechanically inferior to native hyaline cartilage and may deteriorate over 3 to 5 years.
• Osteochondral Autograft Transfer (OATS/Mosaicplasty): Cylindrical osteochondral plugs harvested from a low-load-bearing area of the same joint are press-fitted into the chondral defect, transplanting hyaline cartilage and underlying bone. Produces a hyaline cartilage repair for defects of 1 to 4 cm2 with excellent long-term results in appropriately selected patients, but is limited by donor site morbidity.
• Matrix-Induced Autologous Chondrocyte Implantation (MACI): A two-stage procedure in which chondrocytes are harvested arthroscopically, expanded in a specialist laboratory for 6 weeks, then seeded onto a collagen membrane implanted into the defect at a second surgical procedure. MACI produces durable hyaline-like cartilage repair for lesions of 3 to 10 cm2 in younger patients. Cost is substantially higher than microfracture or chondroplasty.
• High Tibial Osteotomy (HTO): For medial compartment OA or chondral lesions associated with varus malalignment, a corrective osteotomy shifts load to the less-damaged lateral compartment. Highly effective at slowing OA progression and relieving pain in appropriately selected younger patients; often combined with cartilage repair procedures.
• Unicompartmental or Total Knee Replacement: For advanced, diffuse osteoarthritis with significant pain and functional limitation that has failed conservative and joint-preserving measures, partial or total knee arthroplasty provides reliable, durable pain relief and functional restoration. It is the definitive treatment for end-stage OA and is not appropriate for younger patients with focal cartilage lesions.